How p53 mutations drive immunotherapy resistance—and a path to overcome it

Immune checkpoint blockade (ICB) therapy has transformed crab treatment, but galore tumors stay resistant. A caller survey from researchers astatine the Hackensack Meridian Center for Discovery and Innovation (CDI) identifies a antecedently unrecognized mechanics by which mutations successful the p53 cistron tin bounds the effectiveness of immunotherapy—while besides revealing a imaginable strategy to flooded this resistance.